Dirk Beher
Dirk Beher is an experienced biotech executive, serial CEO, board member, drug hunter and entrepreneur. In addition to his executive background, his long-standing (>25 years) CNS drug discovery and development experience is particularly relevant to FundaMental Pharma’s ambition to overcome barriers in treatment-resistant depression. He previously co-founded and served for a decade as the CEO of Asceneuron.
Prior to biotech, Dirk spent 14 years in biopharmaceutical drug discovery leading CNS-focused R&D teams around the globe at Merck Sharp & Dohme (Merck & Co.; UK), Amgen (US) and Merck Serono (CH).
Dirk holds a German Diploma (MSc) and PhD from the Heidelberg University, Germany. He has authored over 50 peer reviewed scientific articles & reviews and is an inventor of multiple granted and pending patents.
ArticleWhy NMDA receptor modulation remains central to next-generation depression therapies
A key player in brain communication and mood regulation, the pharmaceutical industry views the NMDAR as the central pillar for next-generation therapies for depression. Dirk Beher from FundaMental Pharma reveals new strategies for targeting this important receptor.